Teva Undertaking Strategic Review As It Searches For New CEO

Execs were pushed for details during earnings call but offer minimal clarity. Teva is sticking by the guidance issued before its loss in Copaxone patent case, and is upping investment in promoting the brand while the decision is appealed.

Desperate businessmen

Just a week out from losing its CEO, Teva Pharmaceutical Industries Ltd. needed to report annual results from a tough year and face tough questions about the company’s direction. And while management noted that a full review was taking place, most of those questions will remain unanswered until a new CEO is in place.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business